Tetsuro Yasui

Tetsuro Yasui

Auto-generated profile, based on publicly available information

Tetsuro Yasui

Department of Orthopaedic Surgery, Teikyo University Mizunokuchi Hospital, Kawasaki-shi, Kanagawa, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2011 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
TYTetsuro Yasui
Tetsuro Yasui
YKYuho Kadono
Yuho Kadono
MNMasaki Nakamura
Masaki Nakamura
YOYasushi Oshima
Yasushi Oshima
TMTakumi Matsumoto
Takumi Matsumoto
STSakae Tanaka
Sakae Tanaka
Previous studies have shown that transforming growth factor β (TGF-β) promotes receptor activator of nuclear factor-κB ligand (RANKL)–induced osteoclastogenesis. However, the underlying molecular mechanisms have not been elucidated. When TGF-β signals were blocked either by a specific inhibitor of TGF-β type 1 receptor kinase activity, SB431542, or by introducing a dominant-negative mutant of TGF-β type 2 receptor, RANKL-induced osteoclastogenesis was almost completely suppressed. Blockade of Smad signaling by overexpression of Smad7 or c-Ski markedly suppressed RANKL-induced osteoclastogenesis, and retroviral induction of an activated mutant of Smad2 or Smad3 reversed the inhibitory effect of SB431542. Immunoprecipitation analysis revealed that Smad2/3 directly associates with the TRAF6-TAB1-TAK1 molecular complex, which is generated in response to RANKL stimulation and plays an essential role in osteoclast differentiation. TRAF6-TAB1-TAK1 complex formation was not observed when TGF-β signaling was blocked. Analysis using deletion mutants revealed that the MH2 domain of Smad3 is necessary for TRAF6-TAB1-TAK1 complex formation, downstream signal transduction, and osteoclast formation. In addition, gene silencing of Smad3 in osteoclast precursors markedly suppressed RANKL-induced osteoclast differentiation. In summary, TGF-β is indispensable in RANKL-induced osteoclastogenesis, and the binding of Smad3 to the TRAF6-TAB1-TAK1 complex is crucial for RANKL-induced osteoclastogenic signaling. © 2011 American Society for Bone and Mineral Research.

1 November 2016 in The Journal of Foot and Ankle Surgery
Verified
Journal Article
Closed access
PDF file
YAYusuke Ando
Yusuke Ando
TYTetsuro Yasui
Tetsuro Yasui
KIKazuya Isawa
Kazuya Isawa
STSakae Tanaka
Sakae Tanaka
YTYasuhito Tanaka
Yasuhito Tanaka
YTYoshinori Takakura
Yoshinori Takakura

1 April 2016 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
SCSong Ho Chang
Song Ho Chang
TYT. Yasui
T. Yasui
STS. Taketomi
S. Taketomi
TMTakumi Matsumoto
Takumi Matsumoto
JKJ.R. Kim-Kaneyama
J.R. Kim-Kaneyama
TST. Saito
T. Saito

1 January 2014 in The Journal of Foot and Ankle Surgery
Verified
Journal Article
Closed access
TMTakumi Matsumoto
Takumi Matsumoto
YKYuho Kadono
Yuho Kadono
JNJinju Nishino
Jinju Nishino
KNKozo Nakamura
Kozo Nakamura
STSakae Tanaka
Sakae Tanaka
TYTetsuro Yasui
Tetsuro Yasui

1 January 2000 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
OIO Ishiko
O Ishiko
TST Sumi
T Sumi
TYT Yasui
T Yasui
YMY Matsumoto
Y Matsumoto
NKN Kawamura
N Kawamura
RYR Yamada
R Yamada
We first performed 3 or 4 courses of balloon-occluded arterial infusion (BOAI) chemotherapy in 19 patients with advanced cancer of uterine cervix classified as stage III-IV according to the International Federation of Gynecology and Obstetrics. In the patients in whom the first BOAI resulted in insufficient drug accumulation in tumor tissue, the ovarian arteries and veins were ligated to improve the therapeutic effect. Ultimately simple total hysterectomy and radiotherapy were performed in 9 patients in whom the uterus was resectable (the combination group), and radiotherapy alone was conducted in the other 10 patients in whom hysterectomy was not practicable (the incomplete group). The survival rates were significantly higher in the combination group (2-year survival 88. 9%; 5-year survival 66.7%) than in the incomplete group (p=0.0013).

8 January 2010 in Modern Rheumatology
Verified
Journal Article
Closed access
TYTetsuro Yasui
Tetsuro Yasui
JNJinju Nishino
Jinju Nishino
YKYuho Kadono
Yuho Kadono
TMToshihiro Matsui
Toshihiro Matsui
KNKozo Nakamura
Kozo Nakamura
STShigeto Tohma
Shigeto Tohma
The aim of this study was to investigate changes in the treatment strategy of rheumatoid arthritis (RA) and the prevalence of RA-related surgeries after approval of biologics in Japan and to analyze the impact of biologics on the incidence of orthopedic surgeries using a nationwide observational cohort database of rheumatic diseases [National Database of Rheumatic Diseases by iR-net in Japan (NinJa)]. The proportion of patients using biologics linearly increased from 2004 (1.8%) to 2007 (10.0%), but neither the number nor type of RA-related surgery significantly changed during this period. Patients treated with biologics exhibited relatively more severe disease activity and lower physical function. Among patients using biologics, those who underwent RA-related surgeries exhibited background characteristics of longer disease duration and worse physical function, while disease activity was not different from patients without surgery. These results suggest that the potential value of biologics in avoiding surgical procedure is limited in patients with severe functional disorders caused by long disease duration. Further investigation with a longer observation period is required to obtain more definite conclusions as to the impact of biologics usage on orthopedic surgeries.